Further assessment of 17α-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro

Drug Metabolism and Disposition

Volumn 37, Issue 8, 2009, Pages 1667-1675

  Chang, Shu Ying ^a   Chen, Cliff ^a   Yang, Zheng ^a   David Rodrigues, A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY ETHINYLESTRADIOL; 2 HYDROXY GLUCURONIDE; 3 METHOXY ETHINYLESTRADIOL; 6 HYDROXYMELATONIN; AMFEBUTAMONE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXTROMETHORPHAN; DICLOFENAC; DRUG METABOLITE; ETHINYLESTRADIOL; ETHINYLESTRADIOL 3 O GLUCURONIDE; ETHINYLESTRADIOL 3 O SULFATE; MELATONIN; MEPHENYTOIN; MIDAZOLAM; PACLITAXEL; PHENACETIN; TERFENADINE; TESTOSTERONE; UNCLASSIFIED DRUG; CYP1A2 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; ENZYME INHIBITOR; N DEMETHYLASE; ORAL CONTRACEPTIVE AGENT; RECOMBINANT PROTEIN; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; IN VITRO STUDY; LIVER MICROSOME; MICROSOME; PRIORITY JOURNAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; ENZYMOLOGY; GENETICS; INTESTINE; KINETICS; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; ETHINYL ESTRADIOL; HUMANS; HYDROXYLATION; INTESTINES; KINETICS; MELATONIN; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS;

EID: 67650783190     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.026997     Document Type: Article

References (44)

1. Abernethy DR, Greenblatt DJ, and Shader RI (1984) Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 35:792-797.
2. Atkinson A, Kenny JR, and Grime K (2005) Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33:1637-1647.
3. Balogh A, Gessinger S, Svarovsky U, Hippius M, Mellinger U, Klinger G, Hoffmann A, and Oettel M (1998) Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans? Eur J Clin Pharmacol 54:729-734.
4. Balogh A, Klinger G, Henschel L, Börner A, Vollanth R, and Kuhnz W (1995) Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 48:161-166.
5. Beischlag TV and Perdew GH (2005) ERα-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J Biol Chem 280:21607-21611.
6. Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, and Hall SD (2002) The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 53:67-74.
7. Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, and Yeh LT (2007) P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 22:78-87.
8. 50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2:51-59.
9. Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
10. Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, Wen B, and Rodrigues AD (2008) Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(-)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos 36:2513-2522.
11. Di Marco A, Cellucci A, Chaudhary A, Fonsi M, and Laufer R (2007) High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. Drug Metab Dispos 35:1737-1743.
12. Draper AJ, Madan A, and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61.
13. Facciolá G, Hidestrand M, von Bahr C, and Tybring G (2001) Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 56:881-888.
14. Foti RS and Wahlstrom JL (2008) CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 36:523-528.
15. Galetin A and Houston JB (2006) Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220-1229.
16. Granfors MT, Backman JT, Laitila J, and Neuvonen PJ (2005) Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 78:400-411.
17. Ha HR, Chen J, Freiburghaus AU, and Follath F (1995) Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 39:321-326.
18. Ha HR, Chen J, Krahenbuhl S, and Follath F (1996) Biotransformation of caffeine by cDNAexpressed human cytochromes P-450. Eur J Clin Pharmacol 49:309-315.
19. Hägg S, Spigset O, and Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173.
20. Härtter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Röjdmark S, and Bertilsson L (2001) Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther 70:10-16.
21. Hatorp V, Hansen KT, and Thomsen MS (2003) Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 43:649-660.
22. Hilli J, Korhonen T, Turpeinen M, Hokkanen J, Mattila S, and Laine K (2008) The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism. J Clin Pharmacol 48:986-994.
23. Karjalainen MJ, Neuvonen PJ, and Backman JT (2008) In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol 103:157-165.
24. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, and Hollenberg PF (2002) Effect of 17-α-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 300:549-558.
25. Laine K, Anttila M, Helminen A, Karnani H, and Huupponen R (1999) Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Br J Clin Pharmacol 47:249-254.
26. Laine K, Anttila M, Nyman L, Wahlberg A, and Bertilsson L (2001) CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Eur J Clin Pharmacol 57:137-142.
27. Laine K, Yasar U, Widén J, and Tybring G (2003) A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol 93:77-81.
28. 5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J Pharmacol Exp Ther 321:276-287.
29. Lin HL, Kent UM, and Hollenberg PF (2002) Mechanism-based inactivation of cytochrome P450 3A4 by 17α-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 301:160-167.
30. Ma X, Idle JR, Krausz KW, and Gonzalez FJ (2005) Metabolism of melatonin by human cytochromes P450. Drug Metab Dispos 33:489-494.
31. Maurer TS, Tabrizi-Fard MA, and Fung HL (2000) Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery. J Pharm Sci 89:1404-1414.
32. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
33. Palovaara S, Kivistö KT, Tapanainen P, Manninen P, Neuvonen PJ, and Laine K (2000) Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br J Clin Pharmacol 50:333-337.
34. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, and Laine K (2003) Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 74:326-333.
35. Pepper JM, Lennard MS, Tucker GT, and Woods HF (1991) Effect of steroids on the cytochrome P4502D6-catalysed metabolism of metoprolol. Pharmacogenetics 1:119-122.
36. Roberts RK, Grice J, McGuffie C, and Heilbronn L (1983) Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med 101:821-825.
37. Rodrigues AD and Lu P (2004) Is 17α-ethinyl estradiol an inhibitor of cytochrome P450 2C19? Drug Metab Dispos 32:364-365.
38. Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, et al. (2005) Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 45:1413-1421.
39. Shimada T, Murayama N, Okada K, Funae Y, Yamazaki H, and Guengerich FP (2007) Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. Chem Res Toxicol 20:489-496.
40. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
41. Walsky RL, Astuccio AV, and Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46:1426-1438.
42. Walsky RL, Gaman EA, and Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68-78.
43. Wang B, Sanchez RI, Franklin RB, Evans DC, and Huskey SE (2004) The involvement of CYP3A4 and CYP2C9 in the metabolism of 17α-ethinyl estradiol. Drug Metab Dispos 32:1209-1212.
44. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, and Rodrigues AD (2007) Pharmacokinetic drug interactions involving 17α-ethinyl estradiol: a new look at an old drug. Clin Pharmacokinet 46:133-157.